Incidence of Opportunistic Infections among Adult HIV Positive People Receiving Co-trimoxazole Prophylaxis

Yihun Tariku1, Yaliso Yaya2, Degu Jerene3, Alemu Tamiso4
1,2Arba Minch College of Health Science, Arba Minch, Ethiopia
3Department of Preventive Medicine, School of Public Health, Addis Ababa University, Ethiopia
4Department of Public Health, College of Medicine and Health Science, Arba Minch University, Ethiopia

ABSTRACT
In Ethiopia, Co-trimoxazole prophylaxis therapy (CPT) used to prevent opportunistic infections among people living with HIV is the standard of practice; however incidence of opportunistic infection and their predictors are rarely documented in the country. This was a retrospective follow up study to describe the incidence and predictors of opportunistic infections among 244 adults receiving CPT. Participants were followed for a median time of 72 weeks. During a study period a total of 53 opportunistic infections were recorded; making the overall incidence rate 23.9/100 person-years. High incidence of opportunistic infections is likely to occur if: the clients were married (adjusted hazard ratio (AHR) 1.965; (95% CI: 1.109, 3.451), had history of tuberculosis treatment (AHR: 2.34; (95% CI: 1.05, 5.24)), patients who are indicated for CPT because of both clinical and WHO clinical staging criteria (AHR 2.418 (95% CI:1.02, 5.72 ), and had poor adherence to CPT (AHR, 2.11 (95% CI: 1.19-3.72)). Eventhough adherence is non-substitutable strategy to prevent opportunistic infection, the cohort of HIV patients failed to adhere to CPT, which in turn resulted high incidence of opportunistic infections among them, therefore improving adherence as guideline should be a priority to prevent OIs among people living with HIV in the study region.

Copyright © 2015 Institute of Advanced Engineering and Science. All rights reserved.

Corresponding Author:
Alemu Tamiso,
Department Public Health,
College of Medicine and Health Sciences,
Arba Minch University, Southern Ethiopia.
Email: alemutamiso@yahoo.com

1. INTRODUCTION
Human Immune Virus (HIV) is one of the world health and development challenges, and more than 34 million people are living with HIV and around million new infections occurred in the year 2011 [1],[2]. Regarding prevention and control of HIV/AIDS Ethiopia is showing remarkable results with 1.5 % of adult HIV prevalence [3]. However, opportunistic infections (OIs) continue to be a major cause of morbidity and mortality for people living with HIV in the country [4],[5]. Prophylaxis against common OIs is a recommended strategy to improve the quality of life of people infected with HIV through preventing early morbidity and mortality [4],[6].

Co-trimoxazole (a combination of sulfamethoxazole and trimethoprim) is a broad spectrum safe, well tolerated, low-cost, and widely available antimicrobial agent used as standard care for people living with HIV and also used in primary health care to treat various infections [6]-[10]. The Ethiopian national guideline recommends CPT for people living with HIV if one of the following conditions is fulfilled: 1. WHO clinical stage 2, 3 or 4 in the absence of CD4 count, 2. WHO clinical stage 3 or 4 irrespective of CD4
level, 3. CD4 count \(< 350\) cell/mm$^3$, 4. TB-HIV co-infected patient or 5. patient with a documented prior history of Pneumocystis Carini Pneumonia (PCP) \([6],[7]\).

Studies confirmed that CPT significantly reduces morbidity and mortality in HIV positive people even in the area where the drug is highly resisted or malaria is endemic \([9]-[17]\). Nevertheless, the global implementation of CPT has been rated as sub-optimal \([14],[18]\). In Ethiopia CPT is taking place in 2006 but little has been known about the incidence of common OIs such as bacterial pneumonia, diarrhea disease, septicemia, enteritis, malaria or PCP among HIV positive people on CPT \([4]\). This study aimed to describe the incidence of common OIs among HIV positive people on CPT at Arba Minch Hospital since 2003 which provides care to cohorts of people with HIV.

2. RESEARCH METHOD

2.1. Study setting

This study was conducted at Arba Minch Hospital (AMH) which is located at Arba Minch town, Gamo Gofa Zone, South Ethiopia which is 500 km in south of Addis Ababa. The hospital provides comprehensive HIV care to all HIV positive people within Gamo Gofa zone or out. It is also one of few Ethiopian hospitals who started CPT to patients at the first time. The services are provided by multidisciplinary team which includes physicians, nurses, public health professionals, laboratory technologists, pharmacists, data clerks and volunteer who are adherence supporters. In case of illness, the hospital treats patients according to the national guideline for HIV management.

2.2. Patient selection

All adult patients who were registered from Sep 1, 2008 up to Aug 30, 2011 in chronic HIV care clinic plus who had both medical record chart and ART follow up chart were included in the study. This period was selected in order to have the recent possible 72 week (this period is considered the time period in which CPT is effective) follow up time \([19]\). Out of 768 patients registered within the given period, 244 patients become eligible and followed for maximum of 72 weeks (1.38 person years) based on the time when CPT was initiated as shown in Figure 1.

2.3. Study design and data collection

A retrospective follow up study was used. A structured and pretested data collection checklist was prepared and used to collect demographic, baseline clinical and hematological characteristics and follow up condition of the patients. Two health professionals who had bachelor degree with a special training for HIV care were selected to review records.

Figure 1. Participant inclusion flowchart, Arba Minch Hospital, Ethiopia

Incidence of Opportunistic Infections Among Adult HIV Positif People Receiving .... (Yihun Tariku)
2.4. Statistical analysis

Data were entered into Epinfo 7.1.0 and analyzed using the Statistical Package for the Social Science (SPSS) software package, version 20. The main outcome variables are morbidity (malaria, diarrhea, pneumonia, PCP and enteritis) and time to occurrence of morbidity within 72 weeks.

Survival time was calculated in weeks between the date of CPT initiation and (1) the date of event (morbidity), (2) the date transferred out (TO), (3) the date of the first missed appointment for lost cases, and (4) the date on which the patient completed the 72 weeks of follow up. The Kaplan Meier and Log rank test used to estimate survival probability and compare survival curves respectively. The Cox proportional hazard model was used to assess the relationship between baseline variables and morbidity after checking proportional hazard assumption using global goodness-of-fit test (Schoenfeld's method).

2.5. Ethical approval

Institutional ethical approval was obtained from the research and publication committee ethical review board of university of Gondar, Institute of Public Health. We obtained written permission from Gamo Gofa zone administration and AMH.

3. RESULTS AND ANALYSIS

3.1. Participant profile

Between September, 2008 and August 2011, 1209 patients were enrolled in chronic ART clinic, of them 768 patients were on CPT but only 244 patients who have both medical record and ART follow up chart were included in the study (Figure 1).

3.2. Description of study subject and incidence of OIs

Out of 244 patients 159 (57%) were female with mean age of 34.1 years (SD: 10.1) and most of them were unemployed and urban dweller as shown in Table 1.

| Character        | Number | Percent |
|------------------|--------|---------|
| Sex              |        |         |
| Male             | 105    | 43      |
| Female           | 139    | 57      |
| Occupation       |        |         |
| Self-employed    | 61     | 25      |
| Employed         | 131    | 53.7    |
| No formal education | 54    | 22.1    |
| Education level  |        |         |
| Primary          | 90     | 36.9    |
| Secondary        | 76     | 31.1    |
| Tertiary         | 24     | 9.8     |
| Residence        |        |         |
| Urban            | 207    | 84.8    |
| Rural            | 37     | 15.2    |
| Family size      |        |         |
| 1 -3             | 114    | 46.7    |
| >3               | 130    | 53.3    |
| Age group        |        |         |
| 24 – 33          | 105    | 43      |
| 34 – 43          | 76     | 31.1    |
| >or = 44         | 36     | 14.8    |
| Marital status   |        |         |
| Married          | 142    | 58.2    |
| Other            | 102    | 41.8    |

Participants contributed for 221.327 person-years (PY) of follow up and average period of follow-up was 47.17 (SD± 28.7) weeks. The median CD4 count was 157 (IQR: 79 - 241) cells/mm³. Of the 244 participants 161 (66%) had CD4 < 200 cells/mm³, 226 (92.6%) were on ART and 63 (25.8%) had poor adherence to drugs, of which 22(34.9%) developed OI.

During the follow up period, 53 cases were recorded as having OIs, 11 were lost to follow up, 5 transferred out, 14 stopped treatment, 34 died and 127 did not develop event during follow up. Fifty three cases make the overall incidence rate 23.9/100 PY (95% CI; 18.3, 29.5) of them 37% were malaria, 24.5% were pneumonia, 16.9% were enteritis, 13.2% were diarrhea and 3.8% were PCP. Two or more disease episodes were reported in 2 (3.8%) clients and only 3 (5.7%) patients were admitted to hospital.
3.3. Association of OIs with baseline and follow up characteristics

Overall cumulative probability of survival beyond 72 weeks was 0.74 and the median survival time was 59.7 (95% CI: 56.2, 62.5). Compare patients with TB treatment history, adherence to CPT, criteria to initiate CPT and marital status, had significant association with survival time (Figure 2-5 below respectively). Baseline CD4 count [CHR 0.831 (95% CI: 0.47, 1.48)] and WHO clinical stages [CHR 1.49 (95% CI: 0.85, 2.62)] had no association with survival time.

Figure 2. Kaplan–Meier curve of probability of remaining free from OIs over time, by TB treatment history

Figure 3. Kaplan–Meier curve of probability of remaining free from OIs over time, by level of adherence to Co-trimoxazole prophylaxis
Multiple variable cox regression analysis revile that adherence to CPT was an important predictor of risk for opportunistic infection, CHR was 2.087 (95% CI: 1.208, 3.604) for patients with poor adherence to CPT and AHR was 2.108 (95% CI:11.194-3.72) as shown in Table 2.
4. DISCUSSION

Here we describe incidence of OIs by demographic, baseline clinical condition and follow up result of 244 HIV patients receiving Co-trimoxazole prophylaxis and followed up for median 59.7 weeks in Arba Minch hospital. In these patients diagnosis and treatment heeled according to the national standard of treatment but some diagnosis were conducted syndromeically may exaggerate incidence rate.

This study indicated that, the overall incidence rate of OIs in patients on CPT was 23.9/100 PY (95% CI; 18.3, 29.5), which usually occurred within the first 22 weeks primarily due to malaria and pneumonia, it is higher compared to observational study from South Africa has reported incidence rate 0.48/100 person month [20] but lower than finding from Coˆ t d’Ivoire 0.48/100 person month. The rate of pneumonia is higher compared to the result from Coˆ t d’Ivoire 2.7/100 PY [21] but lower compared with finding from Malawi 37/100 PY. Incidence rate of diarrhea was higher in Uganda and Malawi 10.2/100 PY and 37/100 PY respectively [22],[23].

In this study, patients having poor adherence had a significantly high risk of developing OIs than patients having good adherence (AHR was 2.108 95% CI1.194-3.72); this high rate of infection in poorly adhere patients is might be inconsistence or inappropriate use of drug reduce the efficacy. In this study, marital status of patients significantly affect incidence of OIs; unmarried patients are nearly two times at risk of developing Co-trimoxazole preventable OIs; less support for adherence for unmarried patients might increase risk of developing OIs. Patients initiated CPT if they meet both WHO clinical staging and CD4 count more like develop OIs than patients initiated by ethe r of the criteria;  this might be patients started if they meet both criteria were in advanced stage of disease status.

In this study patients categorized in to two baseline CD4 count (CD4 count < 200 cell/mm³ and CD4 ≥ 200 cell/mm³) were equal likely affected by morbidity; this finding is consistent with findings from other studies [10],[14],[17],[24],[25]. This finding reveal that patients by baseline WHO clinical stage (WHO stage

### Table 2. Predictors of opportunistic infections among HIV positive patient

| Characteristics         | Number | PY  | Event | CHR (95% CI) | AHR (95% CI) |
|-------------------------|--------|-----|-------|--------------|--------------|
| Education               |        |     |       |              |              |
| No formal education     | 54     | 44.44 | 16    | 1            |              |
| Primary                 | 90     | 87.21 | 19    | 0.64 (0.33-1.24) | 0.647 (0.329, 1.271) |
| Secondary               | 76     | 67.54 | 16    | 0.67 (0.33-1.34) | 0.677 (0.335, 1.368) |
| Tertiary                | 24     | 22.13 | 2     | 0.26 (.06-1.13) | 0.252 (0.057, 1.113) |
| Marital status          |        |     |       |              |              |
| Married                 | 142    | 131.88 | 25    | 1            |              |
| Not married             | 102    | 89.44 | 28    | 1.63 (.95-2.79) | 1.965 (1.109, 3.451) |
| Residence               |        |     |       |              |              |
| Urban                   | 207    | 186.23 | 41    | 1            |              |
| Rural                   | 37     | 35.10 | 12    | 2.09 (1.21-3.60) | 1.244 (0.635, 2.436) |
| Family size             |        |     |       |              |              |
| 1-3                     | 114    | 106.88 | 21    | 1            |              |
| 4-12                    | 130    | 114.44 | 32    | 1.42 (0.81-2.45) | 1.74 (0.96, 3.16) |
| Weight                  | 244    | 221.33 | 53    | 0.99 (0.95-1.00) | 0.992 (0.963, 1.020) |
| WHO stage               |        |     |       |              |              |
| I & II                  | 104    | 102.13 | 19    | 1            |              |
| III & IV                | 140    | 119.19 | 34    | 1.49 (0.85, 2.62) | 1.35 (0.69, 2.66) |
| CD4 count               |        |     |       |              |              |
| < 200                   | 161    | 139.33 | 36    | 1            |              |
| ≥ 200                   | 83     | 82    | 17    | .831 (.47, 1.48) | 0.678 (.36, 1.26) |
| TB treatment            |        |     |       |              |              |
| Yes                     | 55     | 53.08 | 7     | 1            |              |
| NO                      | 189    | 168.25 | 46    | 2.04 (0.92, 4.53) | 2.34(1.05, 5.24) |
| Functional status       |        |     |       |              |              |
| Working                 | 159    | 149.67 | 40    | 1            |              |
| Ambulatory & bedridden  | 85     | 71.65 | 13    | 0.66 (0.35, 1.24) | 0.645 (0.337, 1.236) |
| Criteria to indication CPT |   |  | | | |
| CD4 count/ WHO stage    |        |     |       |              |              |
| Low                     | 51     | 55.5  | 6     | 1            |              |
| Both                    | 193    | 165.83 | 47    | 2.6 (1.07, 5.84) | 2.418 (1.02, 5.72) |
| Adherence               |        |     |       |              |              |
| Good                    | 181    | 165.63 | 31    | 1            |              |
| Poor                    | 63     | 55.69 | 22    | 2.09 (1.21-3.60) | 2.108 (1.19-3.72) |
1 or 2 and WHO stage 3 or 4) equally at risk of developing OIs; this finding is consistent with results from other studies [9],[17],[24].

Limitation of the study
Because of the retrospective nature of the data collection, we relied on the available information for the number and types of diseases reported during follow up. Some of the diagnoses were presumptive as there was limited capacity to make definite diagnosis.

5. CONCLUSION
Incidence rate of OIs among HIV positive people treated at Arba Minch Hospital ART clinic was high. More importantly, patient poor adherence to CPT was associated with high risk of incidence rate of OIs. The need to strengthen the strategies to enhance adherence to CPT is strongly recommended. Future research should be done using prospectively design to identify another cause for high incidence rate of OIs and proper time for initiation of CPT.

ACKNOWLEDGEMENTS
We would like to acknowledge Arba Minch Hospital ART clinic staffs and data collectors.

AUTHORS' CONTRIBUTIONS
YT designed the study, supervised data collection, analyzed the data and drafts the manuscript. DJ established the HIV cohort at the hospital. YY participated in design of the study and interpretation of the data. AT, critically reviews the paper and re-structured the manuscript. All authors read and approved the final manuscript.

REFERENCES
[1] The Global HIV/AIDS Epidemic, 2012.
[2] Federal Democratic Republic of Ethiopia, "Country Progress Report on HIV/AIDS Response", In: Federal HIV/AIDS Prevention and Control Office, editor. Adis Ababa, 2012.
[3] Ethiopia Central Statistical Agency, ICF International, "2011 Ethiopia Demographic and Health Survey: Key Findings", Calverton, Maryland, USA: CSA and ICF International, 2012.
[4] Federal Ministry of Health of Ethiopia, "guidelines for management of opportunistic infections and anti retroviral treatment in adolescents and adults in ethiopia", In: Federal HIV/AIDS Prevention and Control Office, editor, 2007.
[5] Chaisson R. E., Gallant J. E., Keruly J. C., Moore R. D., "Impact of opportunistic disease on survival in patients with HIV infection", Aids, vol/issue: 12(1), pp. 29-33, 1998.
[6] Federal Ministry of Health of ethiopia, "gudline for cotrimoxazole prophylaxis in HIV/AIDS care and treatment", Federal HIV/AIDS Prevention and Control Office, editor, 2006.
[7] World Health Organization, "Guidelines on Co-trimoxazole Prophylaxis for HIV-related Infections among Children, Adolescents and Adults: Recommendations for a public health approach", Geneva, WHO, 2006.
[8] Nersesian, Paula, Andrew Fullem, Melissa Sharer, "Co-Trimoxazole Management and Availability: Logistics and Supply Chain Experience in 15 U.S. President’s Emergency Plan for AIDS Relief Countries", Arlington, Va.: USAID’s AIDS Support and Technical Assistance Resources, AIDSTAR-One, Task Order 1, 2011.
[9] Mermin J., Lule J., Ekwaru J. P., Malamba S., Downing R., Ransom R., et al., "Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda", The Lancet, vol/issue: 364(9443), pp. 1428-34, 2004.
[10] Suthar A. B., Granich R., Mermin J., Van Rie A., "Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda", The Lancet, vol/issue: 375(9722), pp. 1278-86, 2010.
[11] Alemu A. W., "Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiya, Ethiopia", Global health action, vol. 3, 2010.
[12] Annalisa Saracino, Nacarapa E. A., Ézio A da Costa Massinga, Domenico Martinelli, Marco Scacchetti, Carlos de Oliveira, et al., "Prevalence and clinical features of HIV and malaria co-infection in hospitalized adults in Beira, Mozambique", Malaria Journal, vol/issue: 11(241), 2012.
[13] Imani P. D., Musoke P., Byarugaba J., Tumwine J. K., "Human immunodeficiency virus infection and cerebral malaria in children in Uganda: a case-control study", BMC pediatrics, vol/issue: 11(1), pp. 5, 2011.
[14] Walker A., Ford D., Gilks C., Munderi P., Sa1i F., Reid A., et al., "Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort", The Lancet, vol/issue: 375(9722), pp. 1278-86, 2010.
[15] Mermin J., Ekwaru J. P., Liechty C. A., Were W., Downing R., Ransom R., et al., "Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study", *The Lancet*, vol/issue: 367(9518), pp. 1256-61, 2006.

[16] Grimwade K., Swingler G., Grimley Evans J., "Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV", *Cochrane Database Syst Rev*, vol. 3, 2003.

[17] Miiro G., Todd J., Mpendo J., Wateria C., Munderi P., Nakubulwa S., et al., "Reduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among Ugandan adults", *Tropical Medicine & International Health*, vol/issue: 14(5), pp. 556-63, 2009.

[18] Maynart M., Lièvre L., Sow P. S., Kony S., Gueye N., Bassène E., et al., "Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal", *Journal of acquired immune deficiency syndromes*, vol/issue: 26(2), pp. 130-6, 2001.

[19] Anthony H., Rony Z., Rhehab C., Felix S., Francis G., Henry K., et al., "Operational research in malawi: making a difference with cotrimoxazole preventive therapy in patients with tuberculosis and HIV", *BMC Public Health*, vol. 11.

[20] Motasim Badri, Rodney Ehrlich, Robin Wood, Gary Maartens, "Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations", *AIDS*, vol/issue: 15(9), pp. 6, 2001.

[21] Xavier Anglaret, Eugène Messou, Timothee Ouassa, Siaka Toure, Nicole Dakoury-Dogbo, Patrice Combe, et al., "Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Co’té d’Ivoire", *AIDS*, vol/issue: 17(4), pp. 10, 2003.

[22] Jonathan Mermin, John Lule, John Paul Ekwaru, Robert Downing, Peter Hughes, Rebecca Bunnell, et al., "Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members", *AIDS*, vol/issue: 19(10), pp. 8, 2005.

[23] van Oosterhout J. J., Lauerfer M. K., Graham S. M., Thumba F., Perez M. A., Chimbiya N., et al., "A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV", *JAIDS Journal of Acquired Immune Deficiency Syndromes*, vol/issue: 39(5), pp. 626-31, 2005.

[24] Wiktor S. Z., Sassan-Morokro M., Grant A. D., Abouya L., Karon J. M., Maurice C., et al., "Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d’Ivoire: a randomised controlled trial", *The Lancet*, vol/issue: 353(9163), pp. 1469-75, 1999.

[25] Wateria C., Todd J., Mwonge R., Whitworth J., Nakiyangi-Miro, Brink A., et al., "Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda", *JAIDS Journal of Acquired Immune Deficiency Syndromes*, vol/issue: 42(3), pp. 373-8, 2006.